Danaher Corp (DHR) stock

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value

$236.98+2.91 (+1.24%)

Close on Oct 29, 2026Market cap $166.59BP/E 42.1Yield –

Earnings

Danaher's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Oct 20, 2026

Q3 FY2026 · estimated, after the close

Revenue, Q2 FY2026

$6.30B

+6.8% on a year earlier

Non-GAAP adjusted diluted net earnings per common share, Q2 FY2026

$1.94

$1.80 a year earlier

Latest guidance

Raised

Jul 20, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Danaher's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q3 FY2026ended Sep 26, 2026	Oct 20, 2026Expected	–	–	–	–	–
Q2 FY2026ended Jun 26, 2026	Jul 21, 2026after the close	$6.30B	+6.8%	$1.23	$1.94	Release
Q1 FY2026ended Mar 27, 2026	Apr 21, 2026after the close	$6.00B	+5.3%	$1.45	$2.06	Release
Q4 FY2025ended Dec 31, 2025	Jan 28, 2026after the close	$6.80B	–	$1.66	$2.23	Release
Q3 FY2025ended Sep 26, 2025	Oct 21, 2025after the close	$6.10B	+5.2%	$1.27	$1.89	Release
Q2 FY2025ended Jun 27, 2025	Jul 22, 2025after the close	$5.90B	+3.5%	$0.77	$1.80	Release
Q1 FY2025ended Mar 28, 2025	Apr 22, 2025before the open	$5.70B	-1.7%	$1.32	$1.88	Release
Q4 FY2024ended Dec 31, 2024	Jan 13, 2025after the close	–	–	–	–	Release
Q3 FY2024ended Sep 27, 2024	Oct 22, 2024after the close	$5.80B	-15.9%	$1.12	$1.71	Release
Q2 FY2024ended Jun 28, 2024	Jul 23, 2024after the close	$5.70B	-20.8%	$1.22	$1.72	Release
Q1 FY2024ended Mar 29, 2024	Apr 23, 2024after the close	$5.80B	-19.4%	$1.45	$1.92	Release
Q4 FY2023ended Dec 31, 2023	Jan 30, 2024after the close	$6.40B	-23.8%	$1.50	$2.09	Release
Q3 FY2023ended Sep 29, 2023	Oct 24, 2023after the close	$6.90B	-10.4%	$1.51	$2.02	Release
Q2 FY2023ended Jun 30, 2023	Jul 25, 2023after the close	$7.20B	-7.7%	$1.49	$2.05	Release
Q1 FY2023ended Mar 31, 2023	Apr 25, 2023after the close	$7.20B	-6.5%	$1.94	$2.36	Release
Q4 FY2022ended Dec 31, 2022	Jan 24, 2023after the close	$8.40B	+3.7%	$2.99	$2.87	Release
Q3 FY2022ended Sep 30, 2022	Oct 20, 2022after the close	$7.70B	+6.9%	$2.10	$2.56	Release
Q2 FY2022ended Jul 1, 2022	Jul 21, 2022after the close	$7.80B	–	$2.25	$2.76	Release
Q1 FY2022ended Apr 1, 2022	Apr 21, 2022after the close	$7.70B	–	$2.31	$2.76	Release
Q4 FY2021ended Dec 31, 2021	Jan 27, 2022after the close	$8.10B	–	$2.39	$2.69	Release
Q3 FY2021ended Oct 1, 2021	Oct 21, 2021after the close	$7.20B	–	$1.54	$2.39	Release
Q2 FY2021ended Jul 2, 2021	Jul 22, 2021after the close	–	–	–	–	Filing
Q1 FY2021ended Apr 2, 2021	Apr 22, 2021after the close	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Jan 28, 2021after the close	–	–	–	–	Filing
Q3 FY2020ended Oct 2, 2020	Oct 22, 2020after the close	–	–	–	–	Filing
Q2 FY2020ended Jul 3, 2020	Jul 23, 2020before the open	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Danaher's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
non-GAAP core revenuenon-GAAP	Q3 FY2026	+2% – +3%	–	New	Jul 20, 2026
Adjusted operating profit margin (non-GAAP)non-GAAP	Q3 FY2026	26.5%	–	New	Jul 20, 2026
Cepheid respiratory revenue	FY2026	$1.60B – $1.70B	–	New	Apr 20, 2026
non-GAAP core revenuenon-GAAP	FY2026	+3% – +4%	+3% – +6%	Lowered	Jul 20, 2026
non-GAAP core revenuenon-GAAP	FY2026	+3% – +6%	–	New	Jan 27, 2026
adjusted diluted net earnings per common sharenon-GAAP	FY2026	$8.35 – $8.50	–	New	Jan 27, 2026
full year adjusted diluted net earnings per common sharenon-GAAP	FY2026	$8.45 – $8.60	$8.35 – $8.55	Raised	Jul 20, 2026

Guidance vs results

The last range Danaher gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	non-GAAP adjusted diluted net earnings per common share	$7.70 – $7.80	$7.80Σ4Q	Within range

Guidance history

Every forecast Danaher put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Jul 20, 2026	full year adjusted diluted net earnings per common share	FY2026	$8.45 – $8.60	Raised
Jul 20, 2026	Adjusted operating profit margin (non-GAAP)	Q3 FY2026	26.5%	New
Jul 20, 2026	non-GAAP core revenue	FY2026	+3% – +4%	Lowered
Jul 20, 2026	non-GAAP core revenue	Q3 FY2026	+2% – +3%	New
Apr 20, 2026	full year adjusted diluted net earnings per common share	FY2026	$8.35 – $8.55	New
Apr 20, 2026	non-GAAP core revenue	FY2026	+3% – +6%	New
Apr 20, 2026	Cepheid respiratory revenue	FY2026	$1.60B – $1.70B	New
Jan 27, 2026	adjusted diluted net earnings per common share	FY2026	$8.35 – $8.50	New
Jan 27, 2026	non-GAAP core revenue	FY2026	+3% – +6%	New
Jan 12, 2026	non-GAAP adjusted diluted net earnings per common share	FY2025	$7.70 – $7.80	Reaffirmed
Oct 20, 2025	adjusted diluted net earnings per common share	FY2025	$7.70 – $7.80	Reaffirmed
Jul 21, 2025	full year adjusted diluted net earnings per common share	FY2025	$7.70 – $7.80	New
Jul 21, 2025	non-GAAP core revenue	FY2025	+3%	New
Apr 22, 2025	adjusted diluted net earnings per common share	FY2025	$7.60 – $7.75	New
Apr 22, 2025	non-GAAP core revenue	FY2025	+3%	New
Jan 26, 2022	Core sales growth (non-GAAP)	Q1 FY2022	+10%	New
Oct 20, 2021	non-GAAP core revenue growth rate including Cytiva	FY2021	+20%	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.